Propantheline

DB00782ApprovedSmall moleculeAnticholinergic Agents

Propantheline is an antimuscarinic agent used to treat urinary incontinence, hyperhidrosis, as well as cramps and spasms of the stomach, intestines, and bladder. A muscarinic antagonist used as an antispasmodic, in rhinitis, in urinary incontinence, and in the treatment of ulcers.

Chemical structure of Propantheline
Mechanism
Curator reviewed
Primary indication
For the treatment of enuresis.Curator reviewed · 2 structured indications
Formula / weight
C23H30NO3 · 368.4892 g/mol (avg)
First approval
Canada, 2001 · United States, 1953
Code names
SC 3171

Resolves to

Compound
UNII1306V2B0Q8CAS298-50-0ChEMBLCHEMBL1180725ChEBI8481PubChem4934KEGGC07506
Clinical / RWD
RxNorm8761ATCA03AB05ATCA03CA34PharmGKBPA164746224
Structure
InChIKeyVVWYOYDLCMFIEM-UHFFFAOYSA-NSMILESCC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC2=CC=CC=C12)C(C)C
Targets
P20309CHRM3P11229CHRM1P08172CHRM2

What you can answer from here — as of September 23, 2026

3Protein targetsEach mapped to UniProt, with action and pharmacological action
Listed above
1,153Drug interactionsStructured to mechanism, not free text
Sign in
2Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
9ContraindicationsEach with its own population and attribute set
Sign in
7Marketed productsAcross 3 countries and 5 labellers
Sign in
2ATC codesIncluding every combination product, plus 16 drug categories
Sign in
25+ReferencesStructured and connected to the statements they support
Sign in

Which drugs share a target with Propantheline, and which of those have an active Phase 3 trial?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In